We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New PCR Variants Evaluated for Global Diagnostics of Leishmaniasis

By LabMedica International staff writers
Posted on 04 Nov 2014
Image: Leishmania detection sensitivity – Percentage of positivity in the different hsp70-PCRs (G, F, N, C), evaluated in the total of 98 clinical pre-confirmed cutaneous or visceral leishmaniasis case samples (All) and in different subsets (Bone marrow, Blood/BC[buffy coat], Lymph node, Skin biopsy) (Phot courtesy of Montalvo et al., September 2014, and the journal Diagnostic Microbiology and Infectious Disease).
Image: Leishmania detection sensitivity – Percentage of positivity in the different hsp70-PCRs (G, F, N, C), evaluated in the total of 98 clinical pre-confirmed cutaneous or visceral leishmaniasis case samples (All) and in different subsets (Bone marrow, Blood/BC[buffy coat], Lymph node, Skin biopsy) (Phot courtesy of Montalvo et al., September 2014, and the journal Diagnostic Microbiology and Infectious Disease).
A study of three new PCR variants based on the leishmanial hsp70 gene, evaluated directly on clinical samples, has demonstrated the new tools to be globally applicable for Leishmania species-level typing in various geographical, clinical, and sampling contexts.

In the diagnosis of leishmaniasis, identification of the causative Leishmania species is also important for treatment and prognosis, as well as for epidemiology (including documentation of sympatric and imported species), identification of new non-human reservoir hosts, and for establishing the link in cases of treatment failure. Three new PCR variants based on the hsp70 (heat-shock protein 70) gene had recently been developed and validated directly (without the need for culturing) on New World clinical samples from Peru.

Now, an international team, led by Prof. Gert Van der Auwera of the Institute of Tropical Medicine (ITM) at Antwerp (Belgium), has evaluated the performance of these PCRs on a set of 133 pre-confirmed positive or negative clinical samples (42 cutaneous and 56 visceral leishmaniasis patients, and 35 negative cases) – all from Old World countries: Italy, Sudan, Israel, and Tunisia. Samples were retrospective (had been previously collected) and included bone marrow, blood, buffy coat, lymph node aspirates, and lesion biopsies.

Results showed that the three new PCRs were more sensitive than those previously described for hsp70, and their respective restriction fragment length polymorphism (RFLP) analyses were more efficient for species identification. Also, in 79% of the confirmed positive samples, the species could be identified directly from original sample DNA.

The study described by Montalvo AM et al. in the September 2014, issue of the journal Diagnostic Microbiology and Infectious Disease suggests that these PCRs have potential for becoming a global reference method for identification of Leishmania species in clinical specimens.

Related Links:

Institute of Tropical Medicine (ITM) at Antwerp


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Clinical Chemistry Analyzer
Envoy 500+
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®

Channels

Clinical Chemistry

view channel
Image

Blood Protein Analysis Reveals Menopause-Associated Signals of Brain Aging

Menopause affects women across midlife and is often accompanied by endocrine changes, hot flashes, brain fog and sleep disturbances. Women spend roughly one third of their lives after the menopause transition,... Read more

Molecular Diagnostics

view channel
Image:(L to R) Co-first author Yuan Feng, PhD, corresponding author Xiaotu Ma, PhD, and co-first author Hanxia Li, PhD, all of the St. Jude Department of Computational Biology. (Photo courtesy of St. Jude Children\'s Research Hospital)

Genomic Profiling Predicts Relapse Risk by Subtype in Pediatric Leukemia

B-cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer, with more than 90% of patients surviving with modern treatments. Outcomes are worse when the disease returns, however, making... Read more

Hematology

view channel
Image: The newly certified products are the CytoCell ATM Deletion FISH Probe, CytoCell IGH Plus Breakapart FISH Probe, CytoCell IGH/FGFR3 Plus Translocation, Dual Fusion FISH Probe, and CytoCell IGH/MYEOV Plus Translocation, Dual Fusion FISH Probe. (Photo courtesy of OGT)

Newly Certified FISH Probes Support Cytogenetic Testing in Blood Cancers

Hematological malignancies such as non-Hodgkin lymphoma, acute lymphoblastic leukemia, chronic lymphoid leukemia, and multiple myeloma require assessment of key cytogenetic abnormalities.... Read more

Immunology

view channel
Image: Study design and collection of lower respiratory tract lining fluid (RTLF) using the PExA instrument. (Aguilera K, Hober A, Greilert Norin N, et al. eBioMedicine, 2026. doi:10.1016/j.ebiom.2026.106538)

Exhaled Breath Particles Reveal Virus-Specific Antibodies in the Lower Airways

Respiratory viruses such as influenza virus, SARS-CoV-2, and respiratory syncytial virus (RSV) require immune protection across the airway mucosa. Antibodies in the respiratory tract lining are important... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Industry

view channel
Image: Onvaro’s commercial portfolio will be anchored by the binx io platform, an FDA-cleared, CLIA-waived molecular point-of-care system with more than 1,000 installed instruments. (Photo courtesy of binx health)

New Diagnostics Company Onvaro Formed to Expand Decentralized Testing

Sapphiros, a diagnostics platform backed by investment funds managed by KKR, and binx health, a point-of-care diagnostics company backed by Hildred, have combined to form Onvaro. The new diagnostics company... Read more